Keyword: Breo

Bracing for generic rivals to its top-selling Advair—and looking to fill the sales gap—GSK nabbed FDA approval for its new respiratory med, Trelegy.

It's an ongoing claim that no one wants to see pharma ads. But you can't argue with data, and people aren't clicking away when the TV ads pop up.

A year after showing its Breo Ellipta could cut down on COPD exacerbations, new data says GSK's med trumps usual care at controlling asthma, too.

Pharma companies’ ad spending jumped again last year to $5.6 billion, up from $5.2 billion in 2015, according to Nielsen data. And Pfizer is in large part to thank.

Respiratory player Vectura can set aside its hopes of snagging a COPD indication for ICS/LABA med Flutiform--at least, for now.

Glaxo has finally reached a milestone it’s been promising for a long time: Sales of its new respiratory launches are now more than offsetting declines from aging COPD giant Advair.

GlaxoSmithKline’s Breo is picking up steam--and drugmaker has some new data it hopes can keep that trend going.

It’s been a long three years for GlaxoSmithKline’s Breo Ellipta. But now, the med is finally coming through.

Pharma's top TV spenders for April featured blockbusters and cliffhangers. The top three--Pfizer's Lyrica, AbbVie's Humira and Sunovion's Latuda--have brought home lots of bacon, but now they're facing their own patent expirations.